Menu

Image of the Day: Switch Gears

A gene responsible for the free-moving, primitive nature of fetal cells is expressed in some breast cancer cells in mice and humans.

Sep 10, 2018
Sukanya Charuchandra

ABOVE: Left panel: Considerable numbers of invasive cancer cells with Sox10 (red) in them can be found outside of mouse tumors in vivo (green cells, outlined). Right panel: The invasive cells are proximal to blood vessels (white).
SALK INSTITUTE/SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE

Agene known to be active in fetal cells is also expressed in aggressive forms of breast cancer, pointing to a possible explanation for cancer cells’ ability to regain the potential to evolve into other types and metastasize to different regions in the body. The findings were published last month (August 30) in Cancer Cell.

The gene in question, Sox10, controls several processes, including cell development and movement, as a transcription factor.

The researchers noticed that breast cancer cells from humans and mice with abundant Sox10 reverted to undifferentiated variants that turned invasive and freely migrated. In a mouse experiment, they observed that disrupting Sox10 function stopped cancer formation in breast cells that had been primed to former tumors. 

C. Dravis et al., “Epigenetic and transcriptomic profiling of mammary gland development and tumor models disclose regulators of cell state plasticity,” Cancer Cell, doi:10.1016/j.ccell.2018.08.001, 2018.

Clarification (September 10): Upon request, we changed the credit for the image from Salk Institute to Salk Institute/Sanford Consortium for Regenerative Medicine. 

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.